A vaccine made from a person's own cells, added to other glioblastoma treatment
Official title: Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial tests a vaccine made from a person's own cells for a brain tumor.
Read our full plain-language summary
What the trial team says
This study is designed with open-label and randomized parallel group to evaluate the efficacy and safety of autologous dendritic cell vaccination (ADCV01) as an add-on treatment for primary glioblastoma multiforme
Key facts
- Registry number
- NCT04115761
- Stage of testing
- Phase 2
- Conditions studied
- GBM
Where it is running
This trial lists 3 sites.
-
Non-US
- Taichung Veterans General Hospital (Taichung)
- Chang-Gung Memorial Hospital at Lin-Ko (Taoyuan)
-
Taiwan
- China Medical University Hospital (Taichung)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.